Endocrine Abstracts

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

Calcitonin assessment in thyroid diseases is recommended when medullary thyroid cancer (MTC) is suspected in fine needle biopsy, as well as in ‘suspicious for a follicular neoplasm’ class, especially oxyphilic type, in patients with germinal RET proto-oncogene mutation and in nondiagnostic biopsy when no surgical treatment is planned. This assessment is also suggested before any planned thyroid surgery to exclude MTC. Beyond diagnosis confirmation it is also suggeste...

Background: Turner syndrome (TS) predisposes to autoimmune diseases such as thyroiditis, coeliac disease, diabetes mellitus type 1, inflammatory bowel diseases, alopecia and vitiligo. The prevalence of autoimmunity increases with age and more than one autoimmune disease can coexist together in one patient. The possible factors leading increased autoimmunity in TS are not clear.Aim: To compare the panel of autoimmunity markers in 37 TS girls (40.5% with 4...

Background: Although recombinant human TSH (rhTSH) is widely used to aid radioiodine treatment of differentiated thyroid cancer (DTC), however, there are data on its effectivness in children and adolescents with DTC.The aim of our retrospective study was to evaluate effectiveness and safety of rhTSH aided radioiodine treatment in DTC patients 18 years of age or younger.Material and Methods: Fifty five children/adolescents (median a...

Calcitonin and carcinoembryonal antigen are biochemical markers of medullary thyroid carcinoma (MTC). Assessment of the dynamics of their serum concentration allow for calculation of their doubling times that are independent risk factors for overall survival and progression-free survival in MTC. It is generally accepted that the dynamics and the doubling times remain stable during follow-up.Aim: The aim of the study was to retrospectively verify the stab...

Introduction: Adrenal cortical carcinoma (ACC) is a rare malignant neoplasm of epithelial origin, derived from the adrenal cortex, with a high tendency to local invasion and distant metastases.Aim: The aim was to assess the effect of serum mitotane concentration during mitotane therapy and identify prognostic factors on the survival of ACC patients.Material and methods: It was a multifactorial analysis of patients from a single end...

Aim of the study: Medullary thyroid cancer (MTC) occurs as hereditary and sporadic form. Hereditary type is a consequence of RET proto-oncogene germline mutations also somatic RET mutations are detectable in sporadic MTC tumors. There is a significant relation between site of mutation and the cancer phenotype as well as a clinical course of the MEN 2 Syndrome as a consequence of the different transforming potential of the RET gene mutations. The aim ...

Introduction: To date, only four tyrosine kinase inhibitors (TKIs) have demonstrated beneficial effect on progression free survival in advanced medullary thyroid cancer (MTC; vandetanib and cabozantinib) andradioiodine-refractory differentiated thyroid cancer (RR-DTC; sorafenib and lenvatinib). However, there is still lack of unequivocal proofs of their significant impact on overall survival. Therefore, treatment-related side effects and their potential impact on quality of li...

Introduction: Germline mutations of RET oncogene result in development of multiple endocrine neoplasia type 2 (MEN 2). There is a strong correlation between type of the RET sequence changes and the aggressiveness of main syndrome feature, medullary thyroid carcinoma (MTC), and the incidence of remaining manifestations, mainly pheochromocytoma (PHEO). For many of the RET germline mutations, the clinical risk have been precisely defined, but there are ...

Targeted therapy based on tyrosine kinase inhibitors (TKIs) constitutes a new treatment modality in thyroid cancer (TC). Their efficacy in prolongation of progression free survival in comparison to placebo has been documented in phase III studies. However, a problem of their tolerability has recently risen as numerous side effects influencing the quality of life may potentially limit their clinical use. Therefore, we decided to carry out a retrospective analysis of the frequen...